Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.
about
Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancerRegulation of ERBB3/HER3 signaling in cancerIntermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS-p110 crosstalk.Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in TumorThe Tribbles 2 (TRB2) pseudokinase binds to ATP and autophosphorylates in a metal-independent mannerTranslating neoadjuvant therapy into survival benefits: one size does not fit all.Disentangling multidimensional spatio-temporal data into their common and aberrant responsesProfiling the HER3/PI3K pathway in breast tumors using proximity-directed assays identifies correlations between protein complexes and phosphoproteins.Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies.Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancerPhase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.Tailoring chimeric ligands for studying and biasing ErbB receptor family interactionsChange or die: targeting adaptive signaling to kinase inhibition in cancer cells.The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.Assessing the efficacy of molecularly targeted agents on cell line-based platforms by using system identification.AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activityTranscriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase.Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitorsHER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.Engineered bivalent ligands to bias ErbB receptor-mediated signaling and phenotypes.A class of genes in the HER2 regulon that is poised for transcription in breast cancer cell lines and expressed in human breast tumorsPhosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition.Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathwayPTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications.Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast CancerFeedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors.Dynamical modeling of uncertain interaction-based genomic networks.A Systems Biology Approach in Therapeutic Response Study for Different Dosing Regimens-a Modeling Study of Drug Effects on Tumor Growth using Hybrid SystemsObatoclax and lapatinib interact to induce toxic autophagy through NOXA.Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum.Two dimensions in targeting HER2.Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitorsIntrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implicationsEfficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidenceBayesian model of signal rewiring reveals mechanisms of gene dysregulation in acquired drug resistance in breast cancer
P2860
Q26862550-D80D1A7A-0297-402E-AA2A-1B7BF4F05AD7Q27024334-1AE9E329-FFC5-43F6-9A9A-CCACFCAB5804Q27315979-1C76423B-591C-4FA9-B6C8-1C44007704ACQ27342948-5F07EA40-910D-496E-BEDF-4C0C367847A8Q28834261-638B569A-BC29-4163-8950-34691E968A86Q30251738-F60F7EB7-336D-4219-A42E-EAB8EC684FBCQ30938497-55CED721-F7E2-4E60-99F0-B097EE05EC21Q30997919-739D55B8-87A9-4631-AD43-12F5A903A612Q33275064-859C3D5B-374E-496A-9EDE-3FD5475C36BDQ33591690-0A17C94C-A768-45C0-AD4A-A79B3C705DABQ33597447-F130AEAE-5AEC-4F30-B1A7-75F60E0B7845Q33601610-ACF5203F-2F81-44ED-B61B-F14F5870636FQ34225871-E3DC965E-25DC-4E81-92D8-B0E45C6535E5Q34349389-0604340B-C671-4498-89DC-3E35E1AF1AC5Q34470371-3D4D5F6E-49D6-4BD5-B326-8D8B07106248Q34511038-819C6A5D-6E2A-47C9-963A-77C3E4D4DA33Q34720797-B5A55469-389C-4E8C-A329-B387AB8E469CQ34960206-73A83C36-64D9-4708-A67B-F4DA4CE00328Q34974436-CA68C352-643E-4A1E-989B-DAECE0B0739FQ35145024-8FFE5001-3EB2-49AA-ABF6-E8F83E386A1EQ35176075-31EF5969-9EEA-439F-9A62-FEB5E0DB3F3FQ35479665-390A92CF-F64B-4D53-9CD4-ED34F06B20CCQ35533503-67694C83-0881-4901-8952-EA430791F05FQ35535547-D8ACB5F5-7DDA-460D-94A2-450493DDD3AEQ35562967-1B20A456-573F-4A60-BDF4-FC1177BB9DBEQ35591518-5CDA348C-52CF-4545-AD6D-AC31F546B76EQ35693389-187DC30A-0268-4B5B-AA6D-5BC6D1A23A6AQ35779022-86D4ED7B-80F0-4115-BA08-22FD8F317AE0Q35794214-863CB547-A026-4739-B425-53F34753A917Q35817902-02CACE29-7A9B-4D3C-9DC4-892F8CA8DC17Q35846880-478B8E7C-55D4-437D-B7CA-3C82B807CB22Q35861503-6FA54181-8283-4611-9DCA-D280B35E04AAQ35889621-ECE0047F-BE8D-4B0B-8111-EE6B128CE54CQ35890128-68637E6F-2C11-4BAE-A4B8-854F4262BBC3Q35895143-C71E112D-7388-440A-A0C6-9DC3193A018BQ35895370-CCAED7BC-E368-4E3A-B95F-38E9B5C02C71Q35967385-CCBE4505-E571-4F44-AC32-EDD90BA73DE2Q36088788-3611A164-B76C-4DC4-A7D1-2C81040B0BFEQ36250585-4AC7052D-4F2A-464D-A8A1-2F172A9AC178Q36306149-8281D755-3AE2-4EAB-ADD0-87A37258414D
P2860
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.
@ast
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.
@en
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.
@nl
type
label
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.
@ast
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.
@en
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.
@nl
prefLabel
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.
@ast
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.
@en
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.
@nl
P2093
P2860
P1476
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.
@en
P2093
Byron Hann
Deepika Ahuja
Dhara N Amin
Donghui Wang
Jimmy A Blair
Kevan M Shokat
Kevin M Koch
Mark M Moasser
Martin McMahon
Natalia Sergina
P2860
P356
10.1126/SCITRANSLMED.3000389
P407
P577
2010-01-01T00:00:00Z